
Browsing restrictions can be lifted for a fee.
0.36%
Zepp health corporation
0.66%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Zepp Health Corporation, together with its subsidiaries, develops, manufactures, and sells smart wearable technological devices in the People's Republic of China. It operates through two segments, Xiaomi Wearable Products, and Self-Branded Products and Others. The company offers smart bands, watches, and scales; and smart hearable products, home treadmill, sportswear, home appliances, and smart watch accessories under the Xiaomi and Amazfit brands. It provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China.
The most recent financial report for Zepp health corporation (ZEPP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZEPP's short-term business performance and financial health. For the latest updates on ZEPP's earnings releases, visit this page regularly.
According to the latest financial report, Zepp health corporation (ZEPP) reported an Operating Profit of -884K with an Operating Margin of -1.17% this period, representing a growth of 92.95% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Zepp health corporation (ZEPP) announced revenue of 75.79M, with a Year-Over-Year growth rate of 78.49%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Zepp health corporation (ZEPP) had total debt of 210.3M, with a debt ratio of 0.36. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Zepp health corporation (ZEPP) held Total Cash and Cash Equivalents of 102.56M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Zepp health corporation (ZEPP) did not achieve the “three margins increasing” benchmark, with a gross margin of 38.2%%, operating margin of -1.17%%, and net margin of -2.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZEPP's profit trajectory and future growth potential.
According to the past four quarterly reports, Zepp health corporation (ZEPP)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
The latest valuation data shows Zepp health corporation (ZEPP) has a Price-To-Earnings (PE) ratio of -8.35 and a Price/Earnings-To-Growth (PEG) ratio of 0.23. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |